Eli Lilly: A 43% ROIC Incretin Leader Priced for ≈ 18% a Year EPS Growth, with No Margin of Safety at USD 1,417.54

優れた成長株の中から「10 年 5 倍」を探す——上振れ視点で問い詰める「もっと大きくなれるか？」

• QHow high is its market ceiling — is it growing a slice of an existing pie, or creating an entirely new market?7/10

  A

  Verdict: Lilly is creating a new market, obesity treated as a chronic disease with drugs, on top of an existing diabetes pie. The patient ceiling is very high and far from reached. The dollar ceiling is lower and is set by net price and payer budgets, not by demand.

  Evidence that this is a new market, not a bigger slice of an old one:

  • In 2023 Morgan Stanley described global obesity drugs as a USD 2.4B category in 2022 and forecast USD 77B by 2030 (Morgan Stanley, 2023). In Q3 2026 Lilly's Mounjaro + Zepbound alone sold USD 16,075M, ≈ USD 64B annualized (Lilly Q3 2026 8-K). Part of Mounjaro is diabetes use, but forecasts from three years ago are already being overtaken.
  • The patient pool is huge: more than 1 billion people were living with obesity in 2022 (SCMP on the Lancet/WHO study).
  • Adoption is still steep. IQVIA volume (MAT, May 2026) shows global branded obesity +81% and US +87%, against +29% for GLP-1 diabetes (Novo Nordisk H1 2026 6-K). GLP-1 RAs were more than 8 of every 100 US prescriptions in June 2026 (Truveta).
  • New patients, not switchers: more than 0.5M people have filled through the Medicare GLP-1 Bridge since 2026-07-01, ≈ 80% of them incretin-naive (Q3 call transcript).
  • New indications widen the market. Zepbound became the first approved drug for obstructive sleep apnea in December 2024 (AASM). In SURPASS-CVOT, tirzepatide was non-inferior to dulaglutide on major cardiovascular events (HR 0.92), with an exploratory 16% lower all-cause mortality (TCTMD).

  The existing pie is diabetes, where Mounjaro (USD 22,965M in 2025) competes with Ozempic and older GLP-1s (Lilly 2025 10-K).

  What caps the dollar ceiling:

  • Price falls as volume grows. Q3 2026 realized price was −15% (US −7%, outside US −29%).
  • Medicare/Medicaid prices are capped at USD 245/month (pharmaphorum), and Novo cuts the Wegovy US list price by ≈ 50% from 2027-01-01.
  • Medicaid obesity coverage fell from 16 states to 13 in 2026 (Stateline).

  The binding limit is how much payers will spend, not how many patients could benefit.

  2026年10月31日
• QCan its revenue at least double over the next five years? Is that growth driven mainly by volume, price, or new businesses?6/10

  A

  Verdict: Doubling from the clean 2026 base by 2031 is possible but not assured. It needs ≈ 15%/yr revenue growth, which means roughly 24%/yr volume growth if net price keeps falling ≈ 7% a year. Volume and new products drive it; price is a headwind.

  Setting the base:

  • 2026 revenue guidance is USD 91–92B, raised from USD 80–83B in February (Lilly Q3 2026 8-K). It includes ≈ USD 2B of non-recurring items, and no further Jardiance milestones remain (Q3 call transcript). The clean base is ≈ USD 89.5B, so doubling means ≈ USD 179B in 2031.
  • Consensus 2028 revenue is ≈ USD 115B (TIKR), ≈ 13%/yr from the clean base. Getting from there to USD 179B would need ≈ 16%/yr in 2029–31.
  • Measured from 2025 (USD 65,179M), a doubling to ≈ USD 130B by 2030 looks much more achievable; the 2028 consensus is already 1.76x 2025.

  Growth is all volume:

  • 2025: volume +50%, price −6%, FX +1% (Lilly 2025 10-K).
  • Q3 2026: volume +53%, realized price −15% (US −7%, or −10% excluding a favorable rebate estimate change; outside US −29%).
  • Management expects 2027 net price to be a headwind "more than offset by volume".

  New business has to add volume on top:

  • Foundayo (oral) made USD 184M in Q3, below the USD 234M consensus (StockTitan), but takes ≈ 4 in 10 oral obesity starts.
  • The retatrutide BLA is planned for Q1 2027.
  • The Medicare Bridge has filled for more than 0.5M people since July, and 7 in 10 new Bridge patients start a Lilly drug.

  Headwinds that make a doubling harder:

  • Novo cuts US list prices for Wegovy by ≈ 50% and Ozempic by ≈ 35% from 2027-01-01 (Novo Nordisk H1 2026 6-K).
  • Semaglutide generics have launched in India, Brazil and Canada.
  • Lilly expects the Medicare Bridge to shift to carriers for 2028.
  • Outside-US price has fallen 25–36% year on year in each quarter of 2026.

  Bottom line: a doubling by 2031 needs volume to keep compounding near 24% for five more years from a USD 89.5B base. That is a high bar after 50%+ years. It is achievable only if obesity coverage keeps widening and price declines do not accelerate.

  2026年10月31日
• QFive years out, what takes over as the next growth engine? Does that “second curve” exist today?5/10

  A

  Verdict: A second curve exists today, but mostly inside the same franchise: next-generation incretins (retatrutide, oral Foundayo) and new indications. Independent curves in Alzheimer's, immunology and oncology are real but small, ≈ USD 0.74B a quarter against USD 16.1B for Mounjaro + Zepbound. A curve that does not depend on incretins is not yet visible at a scale that matters.

  The clock the next engine must beat:

  • Tirzepatide's compound patent runs to 2036 in the US, 2037 in major Europe and 2040 in Japan; US data protection ends in 2027 (Lilly 2025 10-K).
  • Lilly sued ANDA filers on Mounjaro/Zepbound in Delaware in August 2026 (Lilly Q3 2026 10-Q).

  Curve 1, next-generation incretins (strongest):

  • Retatrutide delivered 28.3% mean weight loss at 80 weeks (12 mg) and 30.3% at 104 weeks in TRIUMPH-1 (AJMC). It beat Ozempic 2 mg head-to-head with more than double the weight loss, and the BLA is planned for Q1 2027 (Lilly Q3 2026 8-K). Tolerability is the open question: AE discontinuation was 11.3% vs 4.9% on placebo.
  • Foundayo was approved for obesity on 2026-04-01 and made USD 184M in Q3. It takes ≈ 4 in 10 oral obesity starts and has been submitted for type 2 diabetes.

  Curve 2, new indications for existing molecules. Zepbound is approved for obstructive sleep apnea (AASM). In SURPASS-CVOT, tirzepatide slowed eGFR decline by 3.54 mL/min/1.73 m² at 36 months versus dulaglutide (TCTMD).

  Curve 3, outside cardiometabolic (small). In Q3 2026 (Lilly Q3 2026 8-K):

  • Kisunla USD 193M (+175%), Jaypirca USD 228M (+59%), Ebglyss USD 202M (+59%) and Omvoh USD 114M (+76%), together ≈ USD 737M.
  • Key Products in immunology, oncology and neuroscience grew 100%.
  • All non-cardiometabolic revenue was ≈ USD 4.6B (19% of USD 24,397M), including Verzenio (USD 5,723M in 2025).

  Options being bought:

  • 9M 2026 cash for acquisitions was USD 10,692M (Orna, Ajax, Centessa, Kelonia, AtaiBeckley, Curevo, Merida and others) (Lilly Q3 2026 10-Q).
  • 2025 R&D was USD 13,337M, +21% (Lilly 2025 10-K).

  Honest read: cardiometabolic was 81% of Q3 revenue. After 2031 the likeliest engine is retatrutide plus oral and outcome-driven label expansion, which is the same biology with longer exclusivity. A truly diversified second curve would need several of today's seedlings to grow 10x or more.

  2026年10月31日
• QWhat is its core competitive advantage? Will that moat widen or narrow over the next three to five years?6/10

  A

  Verdict: Lilly's core advantage is clinical superiority in incretins, backed by manufacturing scale and patents to 2036. Over 3–5 years the efficacy and scale moats look set to widen, but pricing power is narrowing. The moat protects volume, not price.

  Moat 1, clinical superiority (widening):

  • Retatrutide reached 28.3% mean weight loss at 80 weeks in TRIUMPH-1 (AJMC). In Q3 it beat Ozempic 2 mg head-to-head with more than double the weight loss (Lilly Q3 2026 8-K).
  • Novo's CagriSema met non-inferiority to tirzepatide 15 mg on weight but not on HbA1c (Novo Nordisk H1 2026 6-K).
  • Prescribers are moving: tirzepatide had the largest March–June 2026 increase (+9.5%), while first-time semaglutide obesity prescribing fell 13.3% (Truveta). 7 in 10 new Medicare Bridge patients start a Lilly drug (Q3 call transcript).
  • The results show it: TTM revenue growth was 45.5% for Lilly vs 5.6% for Novo (StockAnalysis NVO), and Novo guides 2026 adjusted sales and operating profit at 0% to −6% at CER.

  Moat 2, manufacturing scale (widening, but costly):

  • Capex was USD 8,437M in 9M 2026 vs USD 5,294M a year earlier (Lilly Q3 2026 10-Q).
  • Houston (USD 6.5B) and Richmond (USD 5B) plants have broken ground, and a USD 6B Alabama API plant and a USD 3B European oral plant are announced (Lilly Q4 2025 8-K).
  • Scale is a supply and cost barrier few rivals can match. But capex rose from 4.6% of revenue in 2021 to 12.7% TTM.

  Moat 3, patents (stable). Tirzepatide is covered to 2036 in the US, 2037 in Europe and 2040 in Japan (Lilly 2025 10-K). The ANDA suits filed in Delaware in August 2026 are the risk to watch.

  Where it is narrowing:

  • Pricing power: US realized price −7% in Q3 (−10% excluding a rebate estimate change), outside US −29%.
  • Policy anchors: Medicare/Medicaid prices are capped at USD 245/month (pharmaphorum). Novo cuts the Wegovy list price by ≈ 50% from 2027.
  • Generics: semaglutide generics have launched in India, Brazil and Canada.
  • Orals are the weakest link: Foundayo takes ≈ 4 in 10 oral obesity starts, and Novo's Wegovy pill is the incumbent there.

  Net: over 3–5 years the moat widens in efficacy and capacity, the parts that decide who wins the patient. It narrows in price, the part that decides how much each patient is worth.

  2026年10月31日
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?6/10

  A

  Verdict: Yes. Lilly has lived through the loss of its core products more than once, kept investing through failure, and is already cannibalizing its own franchise. It discloses bad news reasonably candidly, though some of its biggest corrections, such as insulin pricing, came under pressure rather than by choice.

  Track record through disruption:

  • Lilly lost Prozac in 2001, which management called "Year X". Then, between 2010 and 2014, it lost exclusivity on Gemzar, Zyprexa, Cymbalta and Evista, which it expected to cut annual revenue by ≈ USD 7B. CEO John Lechleiter refused to "disinvest in any significant way in R&D", kept the dividend and avoided large mergers (Fox Business; Scrip).
  • In 2016 solanezumab failed its Phase 3 EXPEDITION3 trial. Lilly dropped the filing and took ≈ USD 150M in charges (Fierce Biotech), but stayed in the field. Its next amyloid antibody, Kisunla (donanemab), was approved in July 2024 (Pharmaceutical Technology) and sold USD 193M in Q3 2026, +175% (Lilly Q3 2026 8-K).

  Self-disruption now:

  • Foundayo, an oral pill, competes with Lilly's own injectables.
  • Retatrutide (BLA Q1 2027) is built to beat tirzepatide, Lilly's own best-seller.
  • Lilly accepted a deal that trades price for volume: Medicare/Medicaid capped at USD 245/month, with Medicare MFN pricing for new launches (pharmaphorum).

  How it handles bad news (Q3 2026 evidence):

  • It disclosed that US price was −10% excluding a favorable rebate estimate change, not just the headline −7%.
  • It flagged ≈ USD 2B of non-recurring 2026 revenue and said no further Jardiance milestones remain (Q3 call transcript).
  • Foundayo's USD 184M miss against the USD 234M consensus is plain in the reported numbers.

  Weaker points:

  • Lilly cut insulin list prices by 70% and capped out-of-pocket costs at USD 35 only in March 2023, after years of criticism (Managed Healthcare Executive). Insulin-pricing, 340B and US pricing-investigation matters remain open (Lilly Q3 2026 10-Q).
  • Novo sued Lilly for false advertising on 2026-07-21.
  • Size cuts the other way: with cardiometabolic at 81% of Q3 revenue, reinvention now means replacing a ≈ USD 64B annualized franchise. No past cliff was that large.

  If incretins were disrupted, Lilly's hedge is its pipeline and USD 10,692M of 9M 2026 acquisitions. The DNA is there; the scale of the task is new.

  2026年10月31日
• QDoes management — the founders especially — hold a long-term view with interests deeply tied to the company? Are they willing to sacrifice current profit for the payoff five to ten years out?5/10

  A

  Verdict: Lilly has no founder-operator. Its alignment rests on a long-tenured professional CEO with a large personal stake and on the Lilly Endowment's ≈ 9.6% anchor holding. The company is clearly spending today's profit on the 2030s, but executive incentives run on three-year cycles, not five to ten.

  The CEO is a career professional, not a founder:

  • David Ricks joined Lilly in 1996 and has been chair and CEO since 2017 (Lilly 2026 proxy). That is ≈ 30 years at the company and ≈ 10 as CEO.
  • As of 2026-02-25 he beneficially owned 815,535 shares, including 106,693 held by a family foundation. That is ≈ 0.09% of 893.4M diluted shares, worth ≈ USD 1.16B at USD 1,417.54.
  • The ownership guideline is 12x salary (≈ USD 20M on a USD 1.7M salary), and he holds roughly 57x that. Hedging and pledging are prohibited.
  • 2025 pay was USD 36.7M: USD 23.3M in stock, split 50/50 between Shareholder Value Awards (stock-price growth) and Relative Value Awards (TSR vs peers). Both run over three years with a one-year post-vesting hold. The USD 6.5M cash bonus is tied to revenue, EPS and pipeline progress, and a clawback policy applies. This is strong share-price alignment, but the horizon is three years.

  The Endowment is the long-term anchor:

  • Lilly Endowment held 90,376,978 shares, 9.6% of the class, with sole voting power, as of 2026-06-30 (Schedule 13G/A via StockTitan). That is ≈ USD 128B at the anchor price.
  • It is the largest holder, ahead of Vanguard (8.6%) and BlackRock (6.8%) (Lilly 2026 proxy).
  • It is a philanthropic foundation, not an operator, and it is a slow seller: 92,190,516 shares (9.8%) at 2025-12-31.

  Willingness to sacrifice near-term profit:

  • 2025 R&D was USD 13,337M, +21% (Lilly 2025 10-K).
  • TTM capex was USD 10,984M vs USD 1,310M in 2021.
  • 9M 2026 acquisitions cost USD 10,692M, partly funded by USD 8,941M of new long-term debt (Lilly Q3 2026 10-Q). Acquired IPR&D charges of USD 7,541M (584M + 2,776M + 4,181M) were expensed in the first three quarters of 2026 (Lilly Q3 2026 8-K).
  • Historically, Lilly protected R&D through the 2011–14 patent cliff (Fox Business).

  Caveats:

  • Sacrifice is easy today: operating margin still rose to 51.3% TTM.
  • Buybacks at ≈ USD 1,000/share in Q4 2025 and a debt-funded deal spree at peak earnings are acceptable, not exemplary, capital discipline.
  • The board combines the chair and CEO roles.

  Long-term by big-pharma standards, yes. Founder-grade alignment, no.

  2026年10月31日
• QIf it disappeared tomorrow, how badly would customers miss it? Is the way it grows sustainable, without relying on harm to society or regulators?6/10

  A

  Verdict: Customers would miss Lilly badly. It makes the most-chosen incretin and a large share of the class's supply, and Novo could not quickly replace either. Growth is fairly sustainable socially, because it now comes from more patients at falling prices rather than from price increases. The real risks are pricing politics and payer budget fatigue, not regulatory arbitrage.

  How indispensable it is:

  • Physicians are choosing Lilly. Tirzepatide had the largest March–June 2026 prescription increase (+9.5%) (Truveta), 7 in 10 new Medicare Bridge patients start a Lilly drug, and ≈ 80% of the more than 0.5M Bridge fills are incretin-naive (Q3 call transcript).
  • Some benefits have no substitute. Zepbound was the first approved drug for obstructive sleep apnea (AASM). In SURPASS-CVOT, all-cause mortality was 16% lower than on dulaglutide, an exploratory finding (TCTMD).
  • Supply is hard to replace: 9M 2026 capex was USD 8,437M (Lilly Q3 2026 10-Q). Semaglutide would remain, but patients would lose the higher-efficacy option and much of the capacity.

  Is the growth socially and politically sustainable?

  • Price is moving toward patients. The 2025 government deal capped Medicare/Medicaid at USD 245/month with a USD 50 Medicare copay, set a TrumpRx cash price of USD 346 for Zepbound, and added Medicare MFN pricing for new launches (pharmaphorum).
  • Realized price fell 15% in Q3 2026 while volume rose 53% (Lilly Q3 2026 8-K). This is growth with payers, not against them.
  • Compounding is a leak in exclusivity, not something Lilly exploits. The FDA sent 30 warning letters to telehealth firms marketing compounded GLP-1s on 2026-03-03 (FDA). The residual compounded market's size is unknown.

  Sustainability risks:

  • Budget fatigue: Medicaid obesity coverage fell from 16 states to 13 in 2026 (Stateline), and the Bridge shifts to carriers for 2028.
  • Pricing legacy: Lilly cut insulin list prices 70% only in 2023, under pressure (Managed Healthcare Executive). Insulin-pricing, 340B and US pricing-investigation matters are still open.
  • Safety: product-liability suits cover Mounjaro, Trulicity and Zepbound. Retatrutide's AE discontinuation rate was 11.3% vs 4.9% on placebo (AJMC).
  • Public health: WHO has warned that drugs alone will not solve obesity (Bloomberg), so lifelong use for hundreds of millions will keep drawing scrutiny over cost.

  2026年10月31日
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they get better or worse at scale? Where does the money it earns go?8/10

  A

  Verdict: The unit economics are exceptional and have improved with scale: 83.6% gross margin, 51.3% operating margin and ≈ 62% incremental operating margin since 2022. But growth now needs much more capital, and cash is going into plants, R&D and acquisitions at least as much as to shareholders.

  Margins rose with scale (StockAnalysis financials; ratios):

  • Gross margin went from 76.8% in 2022 to 83.6% TTM, and operating margin from 30.3% to 51.3%.
  • Revenue grew ≈ USD 57.9B (USD 28,541M → 86,462M) while operating profit grew ≈ USD 35.7B. That is an incremental operating margin of ≈ 62%.
  • ROIC moved from 33.9% (2022) to 43.7% (2025) and 42.7% TTM.
  • This happened while price fell. In Q3 2026 volume rose 53% and realized price fell 15% (Lilly Q3 2026 8-K), yet the 2026 performance-margin guide rose from 46.0–47.5% to 52.0–52.5%. Fixed-cost leverage is absorbing price cuts, for now.

  Scale is getting more capital-hungry:

  • Capex rose from 4.6% of revenue in 2021 (USD 1,310M) to 12.7% TTM (USD 10,984M) (StockAnalysis cash flow). With D&A near USD 2.1B a year, ≈ USD 8.9B of that is growth capacity.
  • Working capital ballooned in 2025: receivables +61% and inventories +81% against revenue +45% (Lilly 2025 10-K). OCF/net income was 0.81 in 2025 and 0.93 cumulatively over 2021–25. It has improved to 1.11 TTM.
  • The risk: if net price falls faster than volume grows, capacity built at ≈ USD 11B a year will earn lower returns.

  Where the cash goes (TTM):

  • OCF USD 30,645M, capex USD 10,984M, FCF USD 19,661M.
  • Dividends USD 6.0B and buybacks USD 5.8B. The Q3 dividend rose 15% to USD 1.73/share, a 22.5% payout (StockAnalysis statistics). Q4 2025 buybacks averaged USD 1,001.60/share.
  • Acquisitions took USD 10.8B. 9M 2026 deals cost USD 10,692M, partly funded by USD 8,941M of new debt (Lilly Q3 2026 10-Q).
  • R&D comes on top, expensed before FCF: USD 13,337M in 2025.
  • FCF does not cover dividends, buybacks and deals together. Net debt rose from ≈ USD 35.1B to ≈ USD 44.5B in 2026 YTD. That is still only 1.5x TTM OCF.

  Net: each extra dollar of revenue has so far brought in more profit than the last. The next leg depends on whether ≈ USD 11B a year of capex and ≈ USD 10B a year of acquisitions earn anything close to today's 43% ROIC.

  2026年10月31日
• QFor it to rise fivefold in ten years, what conditions must all hold at once? Are they realistic? What expectations does today's share price already imply?3/10

  A

  Verdict: A 5x means a market cap of ≈ USD 6.3T by 2036, which needs net income ≈ 5.6–8.5x today's clean level, delivered in the same year tirzepatide's US patent expires. Several demanding conditions would all have to hold, so this is a low-probability blue-sky case. Today's price already embeds ≈ 18%/yr EPS growth to 2031.

  The arithmetic:

  • 5 × USD 1,266B ≈ USD 6.3T.
  • At 30x that needs net income of ≈ USD 211B; at 20x, ≈ USD 317B.
  • Clean 2026 net income is ≈ USD 37.5B (≈ USD 42 EPS × 893.4M shares). The target is 5.6–8.5x that, or ≈ 19–24% a year for ten years.
  • At the 2026 underlying net margin of ≈ 42.7%, that is ≈ USD 495–740B of revenue: 5.5–8.3x the clean 2026 base of ≈ USD 89.5B, and 3.6–5.4x Lilly and Novo's combined TTM revenue of USD 136.8B (StockAnalysis NVO).

  Is the P/E distorted? Yes, upward:

  • Trailing GAAP P/E is 46.0x (StockAnalysis statistics). But 2026 earnings absorb USD 7,541M of acquired IPR&D in three quarters (584M + 2,776M + 4,181M), and 2026 revenue includes ≈ USD 2B of one-offs (Lilly Q3 2026 8-K).
  • Clean 2026 EPS ≈ USD 42 = guidance midpoint USD 35.50 + ≈ USD 8.25 IPR&D − ≈ USD 1.80 after-tax one-time revenue. On that basis the P/E is ≈ 33.8x; forward P/E is 30.9x.

  All of these would need to hold together:

  1. Obesity drugs become a mass, global chronic therapy, with volume compounding near 20%+ for a decade (Q3 volume: +53%).
  2. Net price stabilizes. Today it is moving the wrong way: −15% in Q3, a USD 245 government cap, and Novo's ≈ 50% Wegovy list cut in 2027.
  3. Retatrutide and its successors carry the franchise past 2036, so a 20–30x multiple still holds at the patent cliff.
  4. Operating margin holds near 50% despite ≈ USD 11B a year of capex.
  5. At least one non-incretin franchise scales from today's ≈ USD 0.74B a quarter.

  Conditions 3 and 4 are plausible, and 1 is credible for the first half of the decade but hard to sustain for all ten years. Condition 2 is deteriorating and condition 5 is unproven, so the joint probability is low.

  What today's price implies:

  • At an 8% discount rate and a 22x 2031 multiple, USD 1,417.54 needs 2031 EPS ≈ USD 95. That is ≈ 18%/yr from USD 42 and ≈ USD 199B of revenue.
  • The 31-analyst average target (USD 1,397.02) is below the price, and our base value on consensus 2028 revenue of ≈ USD 115B is USD 1,141. The price already discounts a strong base case; a 5x needs the blue-sky case on top.

  2026年10月31日
• QWhy hasn't the market grasped all this yet — does it not understand, not respect it, or not see far enough? What would become the “narrative inflection point”?2/10

  A

  Verdict: The market has not missed Lilly. At ≈ USD 1,266B it is priced as the obesity winner, so neither failing to understand it nor looking down on it applies. If anything is mispriced, it is the horizon: the real debate is the 2028–2036 net-price path, and that uncertainty can break either way.

  Evidence the market has already recognized the story:

  • The stock is +74.3% over 52 weeks and +52% since end-April (StockAnalysis statistics; Digrin).
  • 31 analysts rate it a consensus Buy, but their average target of USD 1,397.02 is already below the USD 1,417.54 close.
  • About two-thirds of the move since May is earnings. Underlying 2026 EPS guidance (ex-IPR&D) rose ≈ 19%, from ≈ USD 36.9 to ≈ USD 43.75, against a +28% price move.

  Where the market is cautious, and why:

  • The multiple has compressed even as growth accelerated. Year-end trailing P/E went from 100.0x (2023) to 65.6x (2024) and 46.6x (2025), and is 46.0x now, the bottom of its five-year range (StockAnalysis ratios).
  • Forward P/E of 30.9x compares with a five-year average of 40x (TIKR). On clean 2026 EPS of ≈ USD 42, the P/E is ≈ 33.8x.
  • The market is pricing a fade in 45.5% TTM growth, and Novo shows why. After its own price reset Novo trades at 10.2x trailing, is −22.1% over 52 weeks, and guides 2026 adjusted sales and operating profit at 0% to −6% (Novo Nordisk H1 2026 6-K).

  What may be under-appreciated over a long horizon:

  • The Medicare Bridge has filled for more than 0.5M people, ≈ 80% of them incretin-naive, with 7 in 10 starting on Lilly (Q3 call transcript).
  • Retatrutide's 28.3% weight loss, if approved, could carry the franchise past tirzepatide's 2036 US patent expiry.

  Equally, the market may be too generous: the price needs ≈ 18%/yr EPS growth to 2031 against falling prices.

  Narrative inflection points:

  1. Novo's Q3 results on 2026-11-04 and its Wegovy/Ozempic list cuts from 2027-01-01.
  2. Lilly's Investment Community Meeting on 2026-12-07, then 2027 guidance with Q4 results, estimated for 2027-02-04 (an aggregator estimate, not yet confirmed by Lilly).
  3. US realized price in the Q4 2026 and Q1 2027 8-Ks. Near −3% with 30%+ volume would be a positive inflection; worse than −15% a negative one.
  4. The retatrutide BLA in Q1 2027 and any FDA action on tolerability.
  5. Medicare Bridge renewal or the carrier handoff for 2028, and rulings in the Delaware ANDA suits.

  The narrative will turn on price, not on demand.

  2026年10月31日